In one study, extensive amplification of the ALK fusion gene was detected in 18 patients with lung adenocarcinoma resistant to crizotinib and in acquired drug resistant cell lines with H3122 (including EML4-ALK mutant 1) [144]. The gene discussed is ALK; the disease is lung adenocarcinoma.